Forbes October 19, 2025
A new blood test capable of detecting more than 50 types of cancer has delivered highly promising results in one of the largest interventional screening trials to date. The PATHFINDER 2 study of the Galleri multi-cancer early detection (MCED) test showed a more than seven-fold increase in cancer detection rates when added to standard recommended screenings.
Major Breakthrough in Cancer Screening
Results presented at the European Society for Medical Oncology Congress 2025 in Berlin revealed that more than half of the cancers detected were at an early stage (stage I or II), when they are most treatable. Approximately three-quarters of the cancers detected have no existing standard screening program—such as pancreatic, liver, ovarian, and stomach cancers.
“Cancer is the second...
Today's Sponsors
Today's Sponsor